atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
Helping medical device companies navigate quality, compliance and regulatory pathways with confidence
Bringing a medical device to market requires more than innovative technology. Successful commercialisation depends on robust quality systems, effective risk management and a clear understanding of complex regulatory…
Discover Canada’s healthcare technology leaders connecting with the UK health and life sciences ecosystem
Healthcare innovation is increasingly shaped by international collaboration. By bringing together expertise from different markets, healthcare systems can accelerate the development, validation and adoption of technologies…